SCHEMBL19699596

SCHEMBL19699596

Cc1ncc(-c2ccnc(NC(=O)C(C)C)n2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.46
ADORA1 P30542 2/20 0.44
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
RXFP1 Q9HBX9 1/20 0.41
PIK3CG P48736 1/20 0.40
MAP4K1 Q92918 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
MAPK14 Q16539 1/20 0.37
CDK2 P24941 2/20 0.37
KCNH2 Q12809 1/20 0.37
P2RX3 P56373 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19706527 0.86 NPC1 (0.54) CDC7ADORA1NPC1RAB9ARXFP1
SCHEMBL19699595 0.79 CDC7 (0.46) CDC7ADORA1NPC1RAB9ARXFP1
SCHEMBL19699585 0.75 GSK3B (0.48) ADORA1NPC1RAB9ASMN1; SMN2ADORA3
SCHEMBL19728661 0.74 NPC1 (0.39) ADORA1NPC1RAB9APIK3CGMAP4K1
SCHEMBL19699460 0.74 L3MBTL1 (0.51) CDC7ADORA1NPC1RAB9AKDM4E
SCHEMBL19699609 0.73 ADORA1 (0.73) CDC7ADORA1NPC1RAB9ARXFP1
SCHEMBL14705835 0.73 ABL1 (0.58) ADORA1
SCHEMBL17768101 0.72 GRM4 (0.50) CDC7NPC1RAB9AKDM4EALDH1A1
SCHEMBL19699600 0.70 MKNK1 (0.55) CDC7ADORA1JAK2JAK3DYRK1A
SCHEMBL19699597 0.69 IDH1 (0.49) CDC7ADORA1MAP4K1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362234-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-21 US disclosed
US-20170362234-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-21 US disclosed
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 CDC7 899/4885ADORA1 2592/4885NPC1 3073/4885
US-20170362234-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 CDC7 940/4885ADORA1 2574/4885NPC1 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.